AZTR Azitra, Inc.
Pharmaceutical Preparations · NYSE · SEC CIK 1701478 · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY-98.9%
TTM net income YoY20.5%
TTM EPS YoY71.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-146,468.5%
Net margin-119,566.6%
FCF margin-135,885.3%
EBITDA margin-144,793.5%
Returns
ROE-208.3%
ROA-143.8%
ROIC (approx.)-767.7%
Asset turnover0.00x
Leverage & solvency
Liabilities / assets22.6%
Debt / equity0.00x
Current ratio3.80x
Interest coverage-903.38x
Cash quality & payout
Operating cash flow / net income1.14x
Accruals ratio19.5%
Payout ratio—
Capex / revenue114.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | $0 | $0 | $0 | — | $0 |
| R&D expense | $1.29M | $1.35M | $1.56M | $1.00M | $1.18M | $1.40M | $1.25M | $1.12M |
| SG&A expense | $1.61M | $2.07M | $2.37M | $1.22M | $1.59M | $1.47M | $1.85M | $1.32M |
| Operating income | -$2.91M | -$3.42M | -$3.93M | -$2.23M | -$2.77M | -$2.87M | -$3.10M | -$2.43M |
| Interest expense | $0 | $1,365 | $3,411 | $5,454 | $372 | $468 | $1,293 | $5,612 |
| Pretax income | -$2.95M | -$3.35M | -$3.93M | -$2.23M | -$2.76M | -$2.89M | -$3.07M | -$2.38M |
| Income tax | $0 | $0 | $0 | $8,319 | $0 | $0 | $0 | $9,031 |
| Net income | -$2.95M | -$3.35M | -$3.93M | -$2.23M | -$2.76M | -$2.89M | -$3.07M | -$2.39M |
| EBITDA | -$2.87M | -$3.39M | -$3.90M | -$2.19M | -$2.74M | -$2.84M | -$3.07M | -$2.40M |
| EPS (basic) | -0.29 | -0.17 | -0.25 | — | -6.71 | -1.18 | -1.55 | — |
| EPS (diluted) | -0.29 | -0.17 | -0.25 | — | -6.71 | -1.18 | -1.55 | — |
| Weighted avg. shares (diluted) | 10.30M | 19.30M | 15.52M | — | 411,769 | 2.44M | 1.98M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $3.75M | $6.73M | $10.05M | $2.07M | $1.40M | $1.05M | $3.21M | $4.55M |
| Receivables | $0 | $909 | $5,108 | $912 | $0 | $0 | $0 | $233 |
| Current assets | $4.79M | $7.44M | $10.76M | $3.02M | $2.23M | $1.80M | $3.87M | $5.23M |
| PP&E, net | $520,304 | $536,422 | $530,438 | $548,591 | $579,830 | $601,504 | $621,012 | $653,957 |
| Intangibles | $225,789 | $330,039 | $334,522 | $316,673 | $270,992 | $258,665 | $244,140 | $246,420 |
| Total assets | $5.97M | $8.92M | $12.13M | $5.03M | $4.30M | $3.96M | $5.91M | $7.36M |
| Current liabilities | $1.54M | $1.53M | $1.55M | $1.07M | $1.81M | $1.45M | $1.28M | $1.38M |
| Total liabilities | $1.58M | $1.58M | $1.65M | $1.22M | $2.02M | $1.73M | $1.50M | $1.66M |
| Shareholders' equity | $4.40M | $7.33M | $10.48M | $3.80M | $2.28M | $2.23M | $4.41M | $5.70M |
| Shares outstanding | 6.06M | 60.60M | 16.19M | 1.07M | 5.60M | 17.98M | 14.98M | 1.15M |
| Cash flow statement | ||||||||
| Operating cash flow | -$2.90M | -$3.29M | -$2.48M | -$2.89M | -$2.44M | -$2.82M | -$3.07M | -$2.59M |
| Capital expenditure | $18,394 | $40,053 | $14,928 | $9,249 | $3,363 | $11,601 | $0 | $0 |
| Free cash flow | -$2.92M | -$3.33M | -$2.49M | -$2.90M | -$2.45M | -$2.83M | -$3.07M | -$2.59M |
| Investing cash flow | -$41,989 | -$117,541 | -$37,139 | -$83,858 | -$41,078 | -$36,287 | -$21,686 | -$115,532 |
| Financing cash flow | -$33,215 | $85,482 | $10.50M | $3.64M | $2.84M | $690,343 | $1.75M | -$3,782 |
| Depreciation & amortization | $34,513 | $34,069 | $37,692 | $35,010 | $31,041 | $31,109 | $34,055 | $33,238 |
| Stock-based compensation | $12,937 | $11,405 | $6,149 | $12,146 | $4,165 | $16,031 | $30,402 | $33,178 |
Free plan shows the latest 8 periods; Pro shows all 19 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.